Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 22;9(2):106.
doi: 10.3390/biomedicines9020106.

Liraglutide-Induced Hepatotoxicity

Yaakov Maor  1 , David Ergaz  2 , Stephen D H Malnick  3 , Ehud Melzer  1 , Manuela G Neuman  4
Affiliations

Liraglutide-Induced Hepatotoxicity

Yaakov Maor et al. Biomedicines. .

Abstract

A 52-year-old woman with a BMI of 31.2 kg/m2 was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances in noninvasive techniques enabled this diagnosis to be established. By employing easily quantifiable methods based on serum biomarkers, we could explore a wide variety of endpoints in assessing personalized DILI. In addition, we can test endpoints that are associated with the drug's mechanism of action. Personalized medicine and therapeutic pharmacovigilance of incretin-based hypoglycemic agents are needed to ensure the safety of patients.

Keywords: drug-induced liver injury; liraglutide-induced immune hepatitis; lymphocyte toxicity assay; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. All the authors had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. All the authors contributed to the study concept and design: acquisition, analysis and interpretation of data and drafting of the manuscript and revision of the manuscript for intellectual content. Technical support was provided by In Vitro Drug Safety and Biotechnology.

Figures

Figure 1
Figure 1
Kinetics of liver enzymes during the hospitalization and observation.
Figure 2
Figure 2
Bilirubin kinetics from the moment that the patient was hospitalized, several points after and 11 months after hospitalization.
See this image and copyright information in PMC

References

    1. [(accessed on 19 December 2020)]; Available online: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-an....
    1. Nuffer W.A., Trujillo J.M. Liraglutide: A New Option for the Treatment of Obesity. Pharmacotherapy. 2015;35:926–934. doi: 10.1002/phar.1639. - DOI - PubMed
    1. [(accessed on 6 April 2016)]; Available online: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-an....
    1. Watada H., Kaneko S., Komatsu M., Agner B.R., Nishida T., Ranthe M., Nakamura J. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with ≤50 units insulin degludec in Japanese subjects with type 2 diabetes in a phase 3, double-blind, randomised trial. Diabetes Obes. Metab. 2019;21:2694–2703. doi: 10.1111/dom.13859. - DOI - PMC - PubMed
    1. Nauck M.A., Ghorbani M.L.M., Kreiner E., Saevereid H.A., Buse J.B. LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of Liraglutide Compared with Placebo on Events of Acute Gallbladder or Biliary Disease in Patients with Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019;42:1912–1920. doi: 10.2337/dc19-0415. - DOI - PMC - PubMed

LinkOut - more resources